Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Korro Bio, Inc. (KRRO)

Korro Bio: Novo Nordisk ends collaboration effective Feb. 1, 2027; Q3 net loss $17.5M

Negative Impact 4 of 5 product/contract Written later

On November 3, 2026, Novo Nordisk gave Korro Bio notice that it will terminate their research collaboration and license agreement without cause, effective February 1, 2027. Novo Nordisk did not nominate a second target, and no milestone payments were earned under the agreement. Korro's third-quarter 2026 results showed no collaboration revenue, compared with $1.1 million a year earlier, while the net loss narrowed to $17.5 million from $18.1 million.

Key points

  • Novo Nordisk gave 90 days' notice on November 3, 2026; the termination takes effect February 1, 2027.
  • Korro's $10.0 million upfront payment and other amounts received are non-refundable, and Korro will not incur early termination penalties.
  • Collaboration revenue was zero for the quarter ended September 30, 2026, versus $1.1 million a year earlier.
  • Cash, cash equivalents and marketable securities were $124.8 million at September 30, 2026, with a runway into the second half of 2028.

The filing

CompanyKorro Bio, Inc. (KRRO)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:04 AM ET
Accession number0001193125-26-448532

Items reported: 1.02 Termination of Material Agreement2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.